Modern concepts in the treatment of classical Hodgkin lymphoma in children and adolescents

Cover Page

Cite item

Full Text

Abstract

Over the past century, classical Hodgkin lymphoma (HL) has evolved from a fatal disease to one of the most curable cancers. Treatment protocols for pediatric patients with HL have been developed by the world's major research consortia: the Children's Oncology Group (COG) and the European Network-Paediatric HL Study Group (EuroNet-PHL). Their efforts are devoted to identifying ways to reduce the indications for radiation therapy and to use smaller field sizes and reduced doses of radiation therapy as well as lower doses of chemotherapy with the aim to reduce early mortality and potential toxicity in the long term. These protocols rely on risk-adapted treatment programs based on early response to chemotherapy, which has become a determining factor for the use of radiotherapy. Positron emission tomography has taken a leading role in staging and evaluation of treatment response. The aim of this review is to summarize current understanding of pediatric classical HL treatment according to the approaches of the COG and EuroNet-PHL research consortia.

About the authors

G. I. Shestopalov

Russian Children's Clinical Hospital of the N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: shestopalovgleb@yandex.ru
ORCID iD: 0000-0002-2410-2867
SPIN-code: 2722-8515

Gleb I. Shestopalov - a hematologist of the Department of Bone Marrow Transplantation at the Russian Children's Clinical Hospital of the N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation.

117 bldg. 1, Leninsky prospekt, 119571, Moscow

Russian Federation

E. V. Volchkov

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Email: volchcov.egor@yandex.ru
ORCID iD: 0000-0002-2574-1636

Moscow

Russian Federation

D. A. Evstratov

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Email: evstratov.d.a@yandex.ru
ORCID iD: 0000-0003-2801-7421

Moscow

Russian Federation

N. V. Myakova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Email: nmiakova@mail.ru
ORCID iD: 0000-0002-4779-1896

Moscow

Russian Federation

References

  1. Alaggio R., Amador C., Anagnostopoulos I., Attygalle A.D., Araujo I.B.O., Berti E., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36 (7):1720–48. doi: 10.1038/s41375-022-01620-2
  2. National Cancer Institute: NCCR. An interactive website for NCCR cancer statistics. Bethesda, MD: National Cancer Institute. Last accessed January 5, 2025. [Electronic resource] URL: https://nccrexplorer.ccdi.cancer.gov/ (accessed 04.03.2025).
  3. Malignant neoplasms in Russia in 2016 (incidence and mortality). Edited by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova, Moscow: P. Hertsen Moscow Oncology Research Institute; 2018, p 38. (In Russ.)
  4. Huang J., Pang W.S., Lok V., Zhang L., Lucero-Prisno III D.E., Xu W. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. J Hematol Oncol 2022; 15 (1): 57. doi: 10.1186/s13045-022-01281-9
  5. Satou A., Takahara T., Nakamura S. An Update on the Pathology and Molecular Features of Hodgkin Lymphoma. Cancers (Basel) 2022; 14 (11): 2647. doi: 10.3390/can-cers14112647
  6. Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T., O’Donnell E., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268–77. doi: 10.1182/blood-2010-05-282780
  7. Roemer M.G., Advani R.H., Ligon A.H., Natkunam Y., Redd R.A., Homer H., et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016; 34: 2690–7. doi: 10.1200/JCO.2016.66.4482
  8. Eline Zijtregtop A.M., Zeal J., Metzger M.L., Kelly K.M., Mauz-Koerholz C., Voss S.D., et al. Significance of E-lesions in Hodgkin lymphoma and the creation of a new consensus definition: a report from SEARCH. Blood Adv 2023; 7 (20): 6303–19. doi: 10.1182/bloodadvances.2023010024
  9. Munir F., Hardit V., Sheikh I.N., Qahtani S.A., He J., Cuglievan B., et al. Classical Hodgkin Lymphoma: From Past to Future – A Comprehensive Review of Pathophysiology and Therapeutic Advances. Int J Mol Sci 2023; 24 (12): 10095. doi: 10.3390/ijms241210095
  10. Wirth A., Grigg A., Wolf M., Goldstein D., Johnson C., Davis S., et al. Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group. Leuk Lymphoma 2011; 52 (5): 786–95. doi: 10.3109/10428194.2010.547155
  11. Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E., et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059–67. doi: 10.1200/jCO.2013.54.8800
  12. Flerlage J.E., Kelly K.M., Beishuizen A., Cho S., De Alarcon P.A., Dieckmann U., et al. Staging evaluation and response criteria harmonization (SEARCH) for childhood, adolescent and young adult Hodgkin lymphoma (CAYAHL): methodology statement. Pediatr Blood Cancer 2017; 64: e26421. doi: 10.1002/pbc.26421
  13. Robertson V.L., Anderson C.S., Keller F.G., Halkar R., Goodman M., Marcus R.B., et al. Role of FDG-PET in the definition ofinvolved-field radiation therapy and management for pediatric Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 2011; 80 (2): 324–32. doi: 10.1016/j.ijrobp.2010.02.002
  14. Gallamini A., Fiore F., Sorasio R., Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma 2009; 50 (11): 1761–4. doi: 10.3109/10428190903308072
  15. Kelly K.M., Cole P.D., Pei Q., Bush R., Roberts K.B., Hodgson D.C., et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. Br J Haematol 2019; 187: 39–48. doi: 10.1111/BJH.16014
  16. Schwartz C.L., Chen L., McCarten K., Wolden S., Constine L.S., Hutchison R.E., et al. Childhood Hodgkin International Prognostic Score (CHIPS) predicts event-free survival in Hodgkin lymphoma: A report from the Children’s Oncology Group. Pediatr Blood Cancer 2017; 64: e26278. doi: 10.1002/pbc.26278
  17. Nadali G., Tavecchia L., Zanolin E., Bonfante V., Viviani S., Camerini E., et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998; 91: 3011–6. doi: 10.1182/blood.V91.8.3011.3011_3011_3016
  18. Bien E., Balcerska A., Adamkiewicz-Drozynska E., Rapala M., Krawczyk M., Stepinski J. Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias. Clin Biochem 2009; 42: 1144–57. doi: 10.1016/j.clinbiochem.2009.04.004
  19. Abdelrazik N., Fouda M., Zaghloul M.H., Abbas D. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma. Med Princ Pract 2008; 17: 233–8. doi: 10.1159/000117798
  20. Jost P.J., Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007; 109: 2700–7. doi: 10.1182/blood-2006-07-025809
  21. Ben Arush M.W., Shafat I., Ben Barak A., Shalom R.B., Vlodavsky I., Vlodavsky E., et al. Plasma heparanase as a significant marker of treatment response in children with Hodgkin lymphoma: pilot study. Pediatr Hematol Oncol 2009; 26: 157–64. doi: 10.1080/08880010902754917
  22. Kelly K.M. Hodgkin lymphoma in children and adolescents: improving the therapeutic index. Blood 2015; 126 (22): 2452–8. doi: 10.1182/blood-2015-07-641035
  23. Lo A.C., Dieckmann K., Pelz T., Gallop-Evans E., Engenhart-Cabillic R., Vordermark D., et al. Pediatric classical Hodgkin lymphoma. Pediatr Blood Cancer 2021; 68 (Suppl 2): e28562. doi: 10.1002/pbc.28562
  24. Oeffinger K.C., Stratton K.L., Hudson M.M., Leisenring W.M., Henderson T.O., Howell R.M. Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of LongTerm Morbidity: A Report from the Childhood Cancer Survivor Study. J Clin Oncol 2021; 39 (20): 2266–75. doi: 10.1200/JCO.20.01186
  25. Munir F., Hardit V., Sheikh I.N., Qahtani S.A., He J., Cuglievan B., et al. Classical Hodgkin Lymphoma: From Past to Future – A Comprehensive Review of Pathophysiology and Therapeutic Advances. Int J Mol Sci 2023; 24 (12): 10095. doi: 10.3390/ijms241210095
  26. Tebbi C.K., Mendenhall N.P., London W.B., Williams J.L., Hutchison R.E., Fitzgerald T.J., et al. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59 (7): 1259–65. doi: 10.1002/pbc.2427
  27. Schwartz C.L., Chen L., McCarten K., Wolden S., Constine L.S., Hutchison R.E., et al. Childhood Hodgkin International Prognostic Score (CHIPS) predicts event-free survival in Hodgkin lymphoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2016; 64 (4): e26278. doi: 10.1002/pbc.26278
  28. Henderson T.O., Hu B., Keller F., Pei Q., Wu Y., Hoppe B., et al. AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma. Blood 2023; 142 (Suppl 1): 3084. doi: 10.1182/blood-2023-189652
  29. Schwartz C., Constine L., Villaluna D. A risk-adapted, responsebased approach using ABVE-PC for children and adolescents with intermediateand high-risk Hodgkin lymphoma: The results of P9425. Blood 2009; 114: 2051–9. doi: 10.1182/blood-2008-10-184143
  30. Kelly K.M., Sposto R., Hutchinson R., Massey V., McCarten K., Perkins S., et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 2011; 117 (9): 2596–603. doi: 10.1182/blood-2010-05-285379
  31. Nagpal P., Akl M.R., Ayoub N.M., Tomiyama T., Cousins T., Tai B., et al. Pediatric Hodgkin lymphoma – biomarkers, drugs, and clinical trials for translational science and medicine. Oncotarget 2016; 22; 7 (41): 67551–73. doi: 10.18632/oncotarget.11509
  32. Roth L.G., Keller F., Toledo M.M., Castellino S.M., Forlenza C.J., Catalan M.A., et al. Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study. Blood 2023; 142 (Suppl 1): 1700. doi: 10.1182/blood-2023-186719
  33. Castellino S.M., Pei Q., Parsons S.K., Hodgson D., McCarten K., Horton T., el al. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma. N Engl J Med 2022; 387: 1649–60. doi: 10.1056/NEJMoa2206660
  34. Mauz-Körholz C., Landman-Parker J., Balwierz W., Ammann R.A., Anderson R.A., Attarbaschi A., et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advancedstage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol 2022; 23: 125–37. doi: 10.1016/S1470-2045(21)00470-8
  35. Mauz-Körholz C., Hasenclever D., Dörffel W., Ruschke K., Pelz T., Voigt A., et al. Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study. J Clin Oncol 2010; 28 (23): 3680–6. doi: 10.1200/JCO.2009.26.9381
  36. Dörffel W., Rühl U., Lüders H., Claviez A., Albrecht M., Bökkerink J., et al. Treatment of Children and Adolescents With Hodgkin Lymphoma Without Radiotherapy for Patients in Complete Remission After Chemotherapy: Final Results of the Multinational Trial GPOH-HD95. J Clin Oncol 2013; 31 (12): 1562–8. doi: 10.1200/JCO.2012.45.3266
  37. Kahn J.M., Mauz-Korholz C., Hernandez T., Milgrom S.A., Castellino S.M. Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision Making. Am Soc Clin Oncol Educ Book 2024; 44(3): e432420. doi: 10.1200/EDBK_432420
  38. Lo A.C., Liu A., Liu Q., Yasui Y., Castellino S.M., Kelly K.M., et al. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. JAMA Netw Open 2024; 7 (1): e2351062. doi: 10.1001/jamanetworkopen.2023.51062
  39. Schellong G., Riepenhausen M., Bruch C., Kotthoff S., Vogt J., Bölling T., et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German–Austrian DAL-HD studies. Pediatr Blood Cancer 2010; 55 (6): 1145–52. doi: 10.1002/pbc.22664
  40. Dörffel W., Riepenhausen M., Lüders H., Brämswig J., Schellong G. Secondary Malignancies Following Treatment for Hodgkin’s Lymphoma in Childhood and Adolescence. A Cohort Study With More Than 30 Years’ Follow-up. Dtsch Arztebl Int 2015; 112: 320–7. doi: 10.3238/arztebl.2015.0320

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Shestopalov G.I., Volchkov E.V., Evstratov D.A., Myakova N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.